Zinc is an essential mineral that plays an important role in the body. We previously reported that orally feeding zinc-enriched yeast to mice induces nonrapid-eye-movement sleep. In addition, astaxanthin, an antioxidant abundant in seafood such as salmon and krill, is able to chelate minerals and may promote zinc absorption, which in return may also improve sleep. The purpose of our study was to examine the effect of zinc-rich and astaxanthin-containing food on sleep in humans.
Introduction
Sleep is one of the most important biological activities along with eating and exercising for health maintenance. However, many people complain of insomnia in recent years, concomitantly with the progressive development of advanced technologies [1] . A global epidemiological study of insomnia found that one in three people was experiencing insomnia [2] . A survey in China, Singapore, and Malaysia also found that 17.5% women and 12.9% men had insomnia [3] . The prevalence of insomnia in Japan was 20.5% in women and 17.3% in men [4] . According to a 2002 international comparative study of care-seeking behavior for insomnia, only 25% insomnia sufferers in China and <10% of sufferers in Japan seek treatment for insomnia, contrary to 50% in Europe and the United States [5] . Gamma-aminobutyric acid receptor agonist has been commonly used in sleeping pills to treat insomnia. However, it results in dependency and other
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side effects (lightheadedness and resistance), being difficult to use on a daily basis. Meanwhile, presymptomatic insomnia in healthy individuals can be improved through better living habits and diet. In Europe, functional food ingredients such as melatonin, which affects circadian rhythm [6] , and saffron, which has a sedative effect [7] , are used in addition to cognitive behavioral therapy.
Zinc is an essential mineral that plays a major role in >300 enzyme reactions in the body. Zinc is particularly important for proper growth, sensory organ adjustment, reproductive function, and the maintenance of biological structures such as skin, hair, bone, and nails. It has effects on metabolism of carbohydrates, proteins, lipids, and alcohol, DNA synthesis and repair in cells, and other biological functions [8] . Zinc is also a central metal of the enzyme superoxide dismutase that decomposes active oxygen generated within cells and acts to protect the body from in vivo oxidation such as stress and sunburn [9] . The serum zinc concentration is known to decrease with age [10] . In addition, food additives such as dietary fiber, phosphate compounds, and phytic acid, which are commonly used in current processed foods, inhibit zinc absorption [11] , raising concerns about potential dietary zinc deficiency. Moreover, because zinc is not measured in health checkups or other routine tests, zinc deficiency is only discovered in certain situations such as taste abnormalities or extremely slow skin-wound healing.
We previously found that oral administration of zincenriched yeast to mice induces nonrapid-eye-movement sleep [12] . To verify the effect of zinc-enriched food on sleep, in the present study we used oysters from Miyagi Prefecture in Japan that are rich in zinc to investigate the effect of longterm intake of zinc on sleep in humans. Zinc is absorbed from the small intestine via zinc transporters; however, these transporters are not zinc-specific because they also transport other metals such as iron and copper [13] . Moreover, because zinc absorption is easily inhibited by substances such as phosphate compounds and dietary fiber, the absorption rate of zinc could potentially be enhanced. Astaxanthin, a type of natural fat-soluble carotenoid and a red component of salmon and krill, has both an extremely high antioxidant potential, and a chelating effect on zinc in hydrophobic environments [14] , which gives it the potential to increase zinc absorption. We therefore verified the enhancement of zinc's effect on sleep through its combination with astaxanthin, in addition to examining the effects of zinc itself.
Materials and methods

Subjects and trial design
This trial was conducted in accordance with the principles of the Declaration of Helsinki and international rules for clinical and epidemiological research. This randomized, doubleblind, placebo-controlled parallel group trial was additionally conducted with the approval of the Research Ethics Committee of Tokyo Medical University (approval no.: 2953, approved February 2, 2015) . Trial participants (subjects) were also given full verbal and written explanations of the purpose and content of the trial, restrictions during the trial period, and their rights as subjects, to which they gave their voluntary written informed consent.
Subjects were recruited at HUMA R&D (Contract Research Organization, Tokyo, Japan) and its affiliated clinic, Sleep Total Care Clinic Yoyogi, from February 2, 2015. A total of 1011 men and women, who were aged 20-84 years and who gave their consent to participate, underwent routine biochemical testing, stress marker measurements, and a questionnaire-based survey of sleep feelings using the Pittsburgh sleep quality index (PSQI; Supporting Information Fig. 1 ). Before commencing the trial, the restrictions were explained to the subjects; and checks were made to ensure that during the 12 weeks of the trial, subjects did not develop any irregular sleeping habits nor travel to a different time zone, drink alcohol, or change their exercise or dietary habits. A total of 122 healthy subjects were ultimately chosen with a glycoalbumin level within 15.6-18.3%, not engaged in irregular work hours and therefore capable of sleeping within the average nocturnal sleeping hours. The results of a preliminary experiment measuring wake after sleep onset (WASO) in 16 healthy individuals subjected to zinc-enriched yeast supplementation (150 mg/day containing 10% zinc) or placebo were used to determine the target sample size. The number of subjects required to perform the analysis in order to have an 80 percent chance of getting a p value that's less than 0.05 was calculated as 29.69. This was adjusted to n = 30 that means we had a total of 120 subjects over the four groups. Exclusion criteria were as follows: not receiving a diagnosis of diabetes; irregular sleeping habits during the 12 weeks of the trial; travel to a different time zone; ingestion of sleeping pills; and ingestion of psychotropic drugs including antianxiety drugs, anti-histamines, and drugs with an effect on level of arousal. Two subjects were excluded following interviews with a physician, leaving 120 subjects chosen as trial participants. Of these 120 subjects, one refused to participate, bringing the total number of subjects included in the trial to 119. An employee of HUMA R&D randomized and allocated subjects to four parallel groups of 29-30 subjects using a random number table. Checks were made to ensure that subjects in each group were matched for age, sex, sleep indices, blood test items, and stress markers. The person in charge of allocation created an allocation table, which was presented to the person in charge of distributing the test food. The names of subjects, the random number table and the allocation table were stored in a locked room and managed by a person responsible for maintaining the privacy of these materials until unblinding.
This trial was registered in the UMIN Clinical Trials Registry system on April 13, 2015, by Tokyo Medical University (no. UMIN000017118).
Trial period and activity level measurements
The trial was set for 12 weeks from March 30 to June 30, 2015, during which time subjects ingested the test food daily and underwent continuous measurements of activity level and body positional changes by means of a small activity meter (MTN-210; ACOS Co. Ltd., Iida, Japan). This activity meter was equipped with a 3D acceleration sensor-based detection method and was carried by subjects for 7 days immediately after starting the trial to determine baseline data (Supporting Information Table 1 ). Subjects also wore this activity meter for continuous measurements of activity level and body positional changes during the 13 days preceding the 5th and the 9th week as well as the final 13 days of the trial, used to determine the results for the 1st, 2nd, and 3rd month of treatment, respectively (Supporting Information Fig. 2 ). Continuous activity levels recorded by the activity meters were collected by a data management subcontractor and objective estimates of sleep were averaged over 7 days to decrease effects of daily variation. Recordings were used to calculated total sleep time (TST), sleep onset latency (SOL), WASO, sleep efficiency (SE), frequency, and duration of nocturnal awakenings, and number of body positional changes by means of automatic the analysis software SleepSignAct (Kissei Comtec Co., Ltd., Matsumoto, Japan). The data manager and person in charge of analysis were blinded to the test food intake for each group until completion of their work.
Test foods and distribution method
The test foods were two types of shellfish with different levels of zinc matched for calorie intake. Table 1 shows the different levels of intake. In group A, subjects ingested a 40 g can of boiled scallops (Maruha Nichiro Corporation, Tokyo, Japan) containing 1.1 mg of zinc; in group B, subjects ingested a 40 g can of boiled oyster (Inomataya, Miyagi, Japan) containing 15 mg of zinc; subjects from group C ingested the 40 g can of boiled oyster from group B supplemented with 20 g of North Pacific krill powder containing 1.5 mg of astaxanthin; in group D, subjects simultaneously ingested the placebo (40 g can of boiled scallop) and additional zinc and astaxanthin in the form of food supplement. The amount of 15 mg of zinc was provided from zinc-enriched yeast (Kelatron Corporation, Ogden, Utah, USA), whereas 3 mg of astaxanthin was provided from Haematococcus algae-derived astaxanthin oil (FUJIFILM Corporation, Tokyo, Japan). The group D was established to evaluate the effect of zinc and astaxanthin when provided not directly from food but as a food supplement, in a form of capsule; as well as excluding the possibility that the results observed in group B and C are the consequence of unidentified natural compounds present in the distributed food (oyster and krill), rather than the consequence of the supplementation of zinc and/or astaxanthin. The test food was delivered directly to the "person in charge of test food management" which subsequently distributed it to the subjects on the basis of the allocation table predetermined by the "person in charge of allocation."
Ingestion of the test foods and diary records
During the trial period, subjects were instructed to live a regular life, record their bed times, and wake-up times each morning, have three meals a day with maintaining normal habits (both in frequency and amount). Subjects were also instructed to restrict their consumption of beverages such as coffee and black tea in the evenings after 16:00 to minimize the impact of caffeine, and to refrain from drinking alcohol (if consumed, no more than a single beer). Subjects were additionally requested to avoid excessive exercise and napping except when absolutely necessary. Criteria for exclusion from the analysis were: failure to record 50% of activity level measurements, noticeable changes to daily life such as beginning night shifts or taking a long holiday, napping for long periods of time on a daily basis, and starting to take oral drugs.
Subjects were permitted to cook the test foods and ingest their daily portion at any time each day during the 12 weeks, but were advised to ingest the test food at dinner if possible. Recipes created for this trial by a nutritionist were distributed to subjects to facilitate continuous, easy meals. The testing institution that managed the subjects confirmed that subjects ingested the test food every day by telephone and subjects recorded their own meals in a diary. Subjects also recorded daily lifestyle changes and sleep every day during the trial period.
Self-administered questionnaires
Subjects completed the PSQI questionnaire, which assesses sleep quality, immediately after the beginning of the trial and every 2 weeks after that until the end of the trial.
Blood tests
Subjects underwent measurements of blood glucose-related items (hemoglobin A1c, glycoalbumin, 1,5-anhydroglucitol), serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides) kidney function (blood urea nitrogen, serum creatinine, estimated glomerular filtration rate), liver function (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltranspeptidase), electrolytes (Na, K, Cl), serum zinc concentration, blood pressure, and anthropometric indices (height, weight, body mass index) every 4 weeks, at the same time than completing the PSQI questionnaire.
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Analysis and statistics
Activity levels and body positional changes were automatically calculated using the analysis software SleepSignAct [15, 16] . Automatic assessments by SleepSignAct were used to calculate the frequency and duration of nocturnal awakenings and the number of body positional changes lasting for seven minutes or longer within the night. SOL was the amount of time from bedtime, which was determined by the person responsible for analysis on the basis of body positions and activity levels recorded in the subject's diary, to sleep-onset time, which was determined automatically by the analysis software. These data were used to calculate TST and SE, which was calculated as TST divided by the total time in bed and multiplied by 100. The first 7 days of trial served as baseline, whereas the 13 days preceding the 5th and 9th weeks as well as the 12 days preceding the last day of trial were subject to analysis (all days with the exception of clinic visiting days from the 13 measured days). Days during which nocturnal sleep lasted until past noon the following day; and days during which a nap in excess of 2 hours; or nocturnal activity in excess of one hour were excluded from the analysis. If a subject had >30% of their measurement days excluded from analysis, this subject was excluded from the overall analysis. The person responsible for statistical analyses performed the statistical examinations, using the software SPSS Ver.22 (IBM, Armonk, USA). Repeated measures analysis of variance was used to run nonparametric tests with the level of statistical significance set at p < 0.05.
Results
Analysis subjects
Of the 119 men and women who took part in the trial, eight discontinued their participation for personal reasons, one failed to ingest the test food for 50% of the trial period, six failed to record 50% of their activity measurements from continuous recordings, and seven noticeably changed their daily lifestyle in such a way that they met the exclusion criteria or, provided additional explanations of noticeable changes to their daily lifestyle. All these subjects were excluded from the analysis. Two other subjects withdrew for personal reasons (one discontinued participation in the trial because of an accident from which it took 3 months to recovery; the other discontinued participation in the trial because of hospitalization for bowel obstruction), and one subject who took long naps was excluded, leaving 94 participants subject to analysis.
Serum zinc concentration
Serum zinc concentration was measured every 4 weeks in all the participants. No significant difference could be observed along the 12 week trial, within and between each group (Supporting Information Fig. 3 ). Serum zinc homeostasis was maintained throughout the trial and remained within the range of diurnal variation without changing significantly [17] .
Test food intake rates
The intake rate was 97.8% (84.5%-100.0%) for group A (40 g of boiled scallop placebo test food), 98.0% (88.1%-100.0%) for group B (40 g of boiled oyster), 94.5% (61.2%-100.0%) for group C (40g of boiled oyster and 20 g of North Pacific krill powder), and 98.9% (91.7%-100.0%) for group D (40 g of boiled scallop as the placebo group, soft capsules containing 15 mg of zinc from zinc-enriched yeast and 3 mg of astaxanthin). No difference in intake rate was seen between the groups.
PSQI subjective sleep evaluation
The results of the self-administered PSQI completed by all subjects every 2 weeks are presented in Fig. 1 . Scores for PSQI improved significantly within all groups. However, scores were not significantly higher than the placebo group (group A). The mean rate of change after 12 weeks of administration (±SD) was −2.71 ± 2.90 in group A, −2.04 ± 3.14 in group B, −2.83 ± 3.00 in group C, and −1.66 ± 2.69 in group D (Table 2 ). 
Actigraphic objective sleep evaluation
Effect of food supplementation on TST
No significant difference was noted in any groups in comparison to the placebo group (the means and SDs of each group are listed in Fig. 2A despite the absence of a difference).
Effect of food supplementation on SE
SE was significantly improved in the oyster group (group B) in comparison to the placebo group (respectively 3.78 ± 7.80 versus −1.74 ± 4.94; p = 0.025; Fig. 2B ). No improvement could be observed in the other groups.
Effect of food supplementation on SOL
SOL were significantly improved in the oyster group (group B) and the oyster + zinc-enriched yeast + astaxanthin group (group D) in comparison to the placebo group (−6.46 ± 12.29 and −8.57 ± 8.38 versus 2.78 ± 10.55; p = 0.032 and p = 0.004, respectively; Fig. 2C ).
Effect of food supplementation on the number of body positional changes
Although the number of body positional changes increased in the placebo group (3.74 ± 4.38), this increase was suppressed in the oyster group (group B; 0.71 ± 5.01), the oyster + krill group (group C; 0.58 ± 5.75) and the placebo + zincenriched yeast + astaxanthin group (group D; 0.95 ± 4.33), that ingested zinc. However, the number of body positional changes did not differ significantly from the placebo group (Fig. 2D) . 
Adverse events and other parameters
No adverse events associated with food intake occurred in this trial, and no abnormalities were noted in routine biochemical tests.
Discussion
A subjective evaluation of sleep quality by the mean of a selfreport questionnaire, i.e. PSQI, was unable to detect any significant improvement from zinc-enriched food administration in our study. However, our objective evaluation of sleep, based on the actigraphic recording of activity level, confirmed that sleep was improved, and SE was enhanced, in the groups that ingested zinc-rich food. Zinc-rich food administration significantly shortened SOL, whereas SE was also significantly improved in the group that ingested the combination of zinc-enriched yeast and astaxanthin. The sleep-inducing effect of zinc-enriched yeast already reported in mice [12] has now also been verified in humans. However, a subjective evaluation of sleep quality by the mean of a self-report questionnaire was unable to confirm a significant effect in the groups that ingested zinc-rich oyster in this trial. The present study is therefore consistent with previous findings of poor correlations between PSQI, a subjective measurement method, and actigraphy, an objective and reliable technology [18] [19] [20] . We confirmed that zinc improves sleep when it is ingested for long-term in meals on a daily basis. This effect was achieved not only by ingesting zinc-containing supplements such as zinc-enriched yeast but also by ingesting zinc-rich foods such as oysters. We found from the results of brief self-administered diet history questionnaires, and self-administered questionnaires regarding sleep, that people with low zinc intake sleep poorly, whereas people with adequate daily zinc intake have no problem sleeping (Inoue et al., unpubl. data). Furthermore, people with a low serum zinc concentration sleep shorter than people with a normal zinc concentration; and, sleep also tends to be shorter when zinc concentration is high [21] [22] [23] . A cohort study in children also found that SE is better in those with a high serum zinc concentration [24] , which leads to the conclusion that actively ingesting zinc on a daily basis helps to maintain and improve good sleep overall.
Prasad et al. determined the changes in plasma zinc levels following oral zinc sulphate administration. They measured the peak plasma concentration (225.2 ± 45.5 g/dL) after 2.5 h, and more noticeably observed that the plasma concentration reached the near baseline value after 5.5 h [25] . In our study, food intake was done at dinner or lunch time. However, the blood sampling was performed in the morning, at least 10 h after the latest food intake. Therefore, while the zinc-rich food supplementation most likely increased serum zinc concentration during the couple of hours following intake and improved sleep function, blood tests confirmed that the baseline zinc concentration remained unchanged in all the groups over the 4-month long experiment.
Although this trial utilized healthy individuals as subjects, many of the trial participants were working people or homemakers with fixed daily sleeping schedule, which meant that TST calculated from activity levels could not change dramatically. It would be of great interest now to test zinc-enriched food in subjects diagnosed with short night sleep.
Although self-recorded PSQI scores tended to improve in all groups, no significant difference was noted between the groups. Scallops were selected as a placebo food because these are a shell-type seafood and therefore share similar components, texture, and taste with oysters, but in comparison contain a very little amount of zinc. However, scallop also contained ingredients with an anticipated effect on fatigue, such as taurine, vitamin B, and amino acids, which may have provided the sensation of improved sleep, thus possibly having an unexpected impact on the self-recorded subjective evaluation.
In the objective evaluation of sleep indices by actigraphy, the placebo group had decreased SE and a tendency for an increased number of body positional changes; however, the zinc groups had improved SE and a decreased number of body positional changes, which objectively demonstrated a tendency for deeper sleep. This trial took place from spring to summer, when sleep generally tends to worsen as temperature and humidity rises in Japan. Therefore, the results further verified that ingesting zinc is expected to improve sleep in healthy individuals who are dissatisfied or uneasy about their sleep.
An earlier cohort study analyzing the effect of nutrients on sleep reported that low content of zinc in food intake was positively correlated to the low sleep amount, whereas normal sleepers were ingesting a higher amount of zinc, which is consistent with the results of our present study [26] . Ingesting zinc-rich food on a daily basis improves the ease of falling asleep by shortening SOL. It also allows people to sleep soundly for a fixed period of time, decreases the frequency of nocturnal awakenings, and improves the quality of sleep overall by enhancing SE, thereby regulating biological rhythm.
Although we initially speculated that ingesting astaxanthin and zinc-rich food simultaneously would allow astaxanthin to promote zinc absorption, we were unable to confirm a difference in the rate of absorption as a result of astaxanthin. As North Pacific krill-derived astaxanthin is an astaxanthin fatty acid diester, astaxanthin absorption is slow, which might explain why an effect could not be confirmed.
Overall, our findings indicated that ingesting zinc-rich foods such as oyster to replenish zinc contributed to the maintenance of zinc homeostasis in healthy individuals, which was tied to improved sleep. 
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